Alopecia associated with quetiapine

International Clinical Psychopharmacology

Volumn 22, Issue 2, 2007, Pages 117-119

  McLean, Rachael M ^a   Harrison Woolrych, Mira ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse drug reaction; Alopecia; Atypical antipsychotic medicines; Intensive Medicines Monitoring Programme; Quetiapine

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLONAZEPAM; QUETIAPINE; SALBUTAMOL; TRANYLCYPROMINE; VALPROIC ACID; ZOPICLONE;

ADULT; ALOPECIA; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DEPRESSIVE PSYCHOSIS; DISEASE COURSE; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HAIR LOSS; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; REFERENCE DATABASE; WORLD HEALTH ORGANIZATION;

ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ALOPECIA; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CITALOPRAM; CLONAZEPAM; DIBENZOTHIAZEPINES; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES;

EID: 33846990893     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280117fff     Document Type: Article

References (7)

1. Harrison-Woolrych M, Coulter DM (2006). PEM in New Zealand. In: Andrews E, Mann R, editors. Pharmacovigilance, 2nd ed. Chichester: John Wiley & Sons.
2. Hunt N, McHale S (2005). The psychological impact of alopecia. BMJ 331:951-953.
3. Kimyai-Asadi A, Harris JC, Nousari HC (1999). Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 60:714-725.
4. Leung M, Wrixon K, Remick R (2002). Olanzapine-induced hair loss. Can J Psychiatry 47:891-892.
5. Mercke Y, Sheng H, Khan T, Lippmann S (2000). Hair loss in psychopharmacology. Ann Clin Psychiatry 12:35-42.
6. Meyboom RHB, Royer RJ (1992). Causality classification at pharmacovigilance centres in the European community. Pharmacoepidemiol Drug Safety 1:87-97.
7. Tosti A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F (1994). Drug-induced hair loss and hair growth. Drug Safety 10:310-317.